Dual targeting of BCR-ABL1 and IRE1α is a promising therapeutic strategy in Ph+ ALL
Ontology highlight
ABSTRACT: BCR-ABL positive acute lymphoblastic leukemia (ALL) cell survival is strongly dependent on the IRE1α-XBP1 branch of the Unfolded Protein Response (UPR). In the study at hand, we have focused on exploring the link between BCR-ABL1 and IRE1α to better understand whether a simultaneous pharmacological inhibition of both pathways could represent a beneficial therapeutic strategy in Philadelphia positive (Ph+) ALL. Therefore, the effect on the phosphoproteome of two inhibitors (MKC-8866 and Nilotinib) as well as a combination of both compounds was analysed in this study.
INSTRUMENT(S):
ORGANISM(S): Homo Sapiens (human)
TISSUE(S): Blood Cell, Cell Culture, Blood
DISEASE(S): Acute Leukemia
SUBMITTER:
Christian Preisinger
LAB HEAD: Iris Appelmann
PROVIDER: PXD012024 | Pride | 2020-09-21
REPOSITORIES: Pride
ACCESS DATA